Bioprocessing Innovations

Online Summit 2024

Agenda

Session 1
Panel Discussion
1.00 – 2.00pm

Panel Discussion

Challenges in Cell Line Development

The panel discussion will feature distinguished experts in biotechnology and life sciences examining the intricate challenges associated with cell line development. The session will address key issues, including time-to-market considerations, optimization of clone selection, assurance of product consistency, and compliance with regulatory standards. Additionally, topics such as data management and the application of AI in cell line development will be discussed. Expert insights into cutting-edge methodologies and technologies aimed at enhancing the efficiency and reliability of cell line development processes will be shared. This discussion is designed to provide a comprehensive understanding of the complexities involved and to foster knowledge exchange among professionals dedicated to advancing biopharmaceutical research and production.

Session 2
Product Launch
2.15 – 2.30pm

Automated Clone Screening

Introduction of a new automated clone screening system

In this insightful session, we will feature an exclusive interview with Dr. Sebastian Hofzumahaus, the Product Manager, focusing on top clone screening. This discussion will delve into the innovative features and capabilities of the new platform, which is designed to streamline and enhance the efficiency of clone screening in cell line development. Dr. Hofzumahaus will provide an in-depth overview of how the new system addresses critical challenges in the selection of high-performing clones, ensuring genetic stability, and maintaining product consistency.

Key topics will include the platform’s advanced screening methodologies, data management capabilities, and integration with existing workflows. Attendees will gain valuable insights into how the new planform can optimize the clone selection process, reduce time-to-market, and improve overall productivity in biopharmaceutical development. This session is an excellent opportunity for professionals involved in cell line development to learn from an expert and explore cutting-edge solutions for top clone screening.

Global Commercial Product Manager
Beckman Coulter Life Sciences
Session 3
Product Demonstration
2.45 – 3.00pm

Automated Clone Selection

New System Demo

Welcome to our live product demonstration of our new automated clone screening system, an innovative platform designed to revolutionize clone screening in cell line development. In this session, you will experience firsthand how the system can streamline and enhance the efficiency of your clone selection process. Our expert presenters will walk you through the platform’s advanced features, including its robust screening methodologies, intuitive user interface, and seamless integration with existing workflows.

The new system is engineered to address key challenges such as ensuring genetic stability, maintaining product consistency, and accelerating time-to-market. By leveraging cutting-edge technologies, the new system optimizes the identification and selection of high-performing clones, ultimately driving productivity and reliability in biopharmaceutical development.

Join us as we explore the capabilities of the new clone screening system in detail and demonstrate its potential to transform your cell line development processes. Whether you are an industry veteran or new to the field, this live demo promises to provide valuable insights and practical knowledge to enhance your research and production efforts.

Technical Product Manager (TBC)
Beckman Coulter Life Sciences
Global Commercial Product Manager
Beckman Coulter Life Sciences
Session 4
Presentation
3.15 – 3.30pm

The New Clone Screening System

R&D Data Presentation

Anna Kress will delve into the intricacies of R&D data generation using the new automated clone screening platform in this enlightening session. The presentation will provide a comprehensive overview of how the system facilitates robust data collection and analysis throughout the research and development process. Dr. Kress will highlight the platform’s capabilities in generating high-quality, reliable data that drives informed decision-making in cell line development.

Key topics will include advanced data acquisition techniques, integration with existing laboratory workflows, and the utilization of the new platform’s analytical tools to enhance research outcomes. The session aims to provide a deeper understanding of how the new system can optimize data generation, improve efficiency, and support the advancement of biopharmaceutical research.

This presentation offers an invaluable opportunity to explore the benefits of the new platform in elevating R&D data quality and accelerating the development pipeline. Dr. Kress’s expertise and insights promise to provide practical knowledge and innovative strategies for leveraging this powerful platform in research endeavors.

Technical Product Manager (TBC)
Beckman Coulter Life Sciences
Session 5
Panel Discussion
3.45 – 4.45pm

Panel Discussion

Challenges in Analytical characterization of mAbs & ADCs and process optimization of cell culture & media:

Leading experts in the field will focus on critical challenges in analytical characterization of monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), as well as process optimization of cell culture and media. The session will address key issues, including advanced analytical techniques for mAbs and ADCs, ensuring product quality and consistency, and overcoming hurdles in cell culture and media optimization. Additionally, the integration of data management strategies and compliance with regulatory standards will be discussed. Expert insights into innovative methodologies and technologies aimed at enhancing the efficiency and robustness of these processes will be shared. This discussion aims to deepen the understanding of these complex issues and to drive collaborative problem-solving among professionals in biopharmaceutical research and production.

Session 6
Case Study
5.00 – 5.30pm

In Solution Characterization

Using Analytical Ultracentrifugation applied to monoclonal antibodies

Analytical ultracentrifugation (AUC) is a powerful technique employed for the characterization of antibodies, offering detailed insights into their size, anisotropy, and interactions. This method involves centrifuging samples to generate sedimentation profiles, which can be analyzed to determine molecular weights, oligomeric states, and conformational changes. AUC is particularly advantageous for antibody characterization as it operates in solution, preserving the native state of the molecules and allowing for the study of their behavior in physiologically relevant conditions. The technique provides high-resolution data critical for understanding antibody stability, aggregation, and complex formation, making it an invaluable tool in the development and quality control of therapeutic antibodies.

Global Market Development Manager
Beckman Coulter Life Sciences
Session 7
Case Study
5.30 – 6.00 pm

Valita Titer & Valita Aggregation Pure assay

High-throughput, automation ready process analytics for monoclonal antibody screening

Learn how the Valita Titer and Valita Aggregation Pure assay can enhance process timelines through high-throughput analysis of monoclonal antibodies in less than 15 minutes. Either measure IgG titer with the Valita Titer assay or protein aggregation using the Valita Aggregation Pure assay. Both plate-based assays follow a simple workflow which enables easy automation with our Biomek i-Series Automated Workstations.

Global Product Manager Cell Health
Beckman Coulter Life Sciences
Senior Product Development Scientist
ValitaCell
Session 8
Case Study
6.00 – 6.30pm

The Vi-CELL BLU Analyzer

Your alternative for the Cedex® Hi-Res

Comparative Performance Analysis of CHO and HEK Cells
Using Vi-CELL BLU Analyzer and Roche Cedex® HiRes Analyzer

Application Scientist (Cell Health BU)
Beckman Coulter Life Sciences
Session 9
Case Study
6.45 – 7.15pm

Case Study

Transition from Vi-CELL XR analyzer to Vi-CELL BLU analyzer – Manual ( How to come to from the XR to the BLU)

Description coming soon

Global Market Development Manager
Beckman Coulter Life Sciences
EU Field Application Specialist
Beckman Coulter Life Sciences
Session 10
Case Study
7.15 – 7.45pm

Bioprocessing 4.0

The role of connectivity and IT security Vi-CELL BLU Analyzer

Bioprocessing 4.0 – the role of connectivity and IT security Vi-CELL BLU Analyzer. Our Product Specialist Anne-Kathrin Barthel Ph.D and Senior IT Specialist Sören Kromrey clarify important customer questions about the Vi-CELL BLU Analyzer.

Topics discussed include:
Type of device design, Transfer of measurement data into customer networks
Data Backup, Data Storage and User authentication

Senior IT Specialist Europe
Beckman Coulter Life Sciences
Session 11
Case Study
7.45 – 8.15pm
yes

Vi-CELL BLU

Analyzer /Sartorius Ambr®250 High Throughput Bioreactor & Ambr®

15 Cell Culture systems Integration

Our Product Manager Daniel Koeffers and Senior IT Specialist Sören Kromrey will present how the Vi-CELL Blu Analyzer can be integrated into Sartorius Ambr®250 High Throughput Bioreactor & Ambr®15 Cell Culture systems

Manager, Global Commercial Product Management Cell Health
Beckman Coulter Life Sciences
Senior IT Specialist Europe
Beckman Coulter Life Sciences
Session 12
Case Study
8.15 – 8.45pm

Safety in Bioprocessing

High volume harvesting in high quality

High-throughput centrifugation thought ahead. Using the Harvest Line System removes the need of non-value-added steps, as extra spins, bottle cleaning, bottle scraping and time for freeze /thaw lysis.

Optimize your workflow for harvest bacterial or yeast cultures, lysate clarification or isolation of vaccine components. The flexible Liner with volumes from 1L up to 2,25 L will minimize the sample contamination risk, your personal exposure to biologics and increase your storage efficiency.

Cell Health and Centrifugation Marketing Team
Beckman Coulter Life Sciences
Session 13
Case Study
8.45 – 9.15pm

Cell Line Development In BEC LS Automation

Summary: Cell line development (CLD) often becomes a bottleneck in biopharmaceutical production due to its complex, labour-intensive, and time-consuming processes. Beckman Coulter’s automated systems address these challenges by integrating advanced robotics, high-throughput screening, and data management to enhance efficiency, accuracy, and speed. Automated systems can be utilized to optimize the entire CLD workflow, starting from single cell seeding, progressing through expansion and selection, and concluding with cryostock generation or upscaling. Here, we provide some key examples of how automation can enhance and facilitate CLD workflows.

Field Project Manager
Beckman Coulter Life Sciences